Invesco
SPRY icon

Invesco’s ARS Pharmaceuticals SPRY Stock Holding History

Invesco’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$312K Buy
38,891
+705
+2% +$6.06K ﹤0.01% 3428
2026
Q1 		$307K Buy
38,186
+956
+3% +$9.16K ﹤0.01% 3332
2025
Q4 		$434K Sell
37,230
-2,879
-7% -$28K ﹤0.01% 3251
2025
Q3 		$403K Sell
40,109
-77,391
-66% -$1.11M ﹤0.01% 3309
2025
Q2 		$2.05M Buy
117,500
+87,551
+292% +$1.26M ﹤0.01% 2571
2025
Q1 		$377K Buy
29,949
+9,961
+50% +$120K ﹤0.01% 3268
2024
Q4 		$211K Sell
19,988
-105,623
-84% -$1.48M ﹤0.01% 3503
2024
Q3 		$1.82M Sell
125,611
-294,964
-70% -$3.51M ﹤0.01% 2644
2024
Q2 		$3.58M Buy
420,575
+9,203
+2% +$81.7K ﹤0.01% 2350
2024
Q1 		$4.2M Buy
411,372
+396,817
+2,726% +$2.96M ﹤0.01% 2336
2023
Q4 		$79.8K Buy
14,555
+1,698
+13% +$7.44K ﹤0.01% 3713
2023
Q3 		$48.6K Buy
12,857
+80
+0.6% +$525 ﹤0.01% 3798
2023
Q2 		$85.6K Sell
12,777
-234,212
-95% -$1.56M ﹤0.01% 3756
2023
Q1 		$1.61M Buy
246,989
+56,127
+29% +$431K ﹤0.01% 2725
2022
Q4 		$1.63M Buy
+190,862
New +$1.24M ﹤0.01% 2721

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco's SPRY Position: Q2 2026 in Review

Invesco increased its ARS Pharmaceuticals (SPRY) stake by 1.8% in Q2 2026, buying an estimated $6.06K and bringing the position to 38,891 shares worth $312K. The position accounts for ﹤0.01% of the portfolio, ranked #3428.

Invesco first reported a position in SPRY in Q4 2022 and has held it in 15 quarters since. The position peaked at $4.2M in Q1 2024. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Invesco held 38,891 shares of ARS Pharmaceuticals worth $312K as of Q2 2026.
  • Invesco bought 705 ARS Pharmaceuticals shares in Q2 2026, an estimated $6.06K.
  • ARS Pharmaceuticals made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3428 holding.
  • Invesco first reported a position in ARS Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Invesco's ARS Pharmaceuticals position peaked at $4.2M in Q1 2024.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.